IP Library › Granted Patent US 12,606,810
Granted Patent B2
US 12,606,810 · App. 17/426,569 · Granted Apr 21, 2026

Subtilase variants and compositions comprising same

Inventors: Nan Gao (Beijing, CN); Carl Mikael Bauer (Malmo, SE); Esben Peter Friis (Herlev, DK); Rolf Thomas Lenhard (Lyngby, DK)
Assignee: Novozymes A/S
C12N9/54C11D3/386C12Y304/21062
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,810
App. No.
17/426,569
Granted
Apr 21, 2026
Kind
B2
Abstract

Provided are subtilase variants having improved stability, detergent compositions comprising the variants, use of the variants and detergent compositions in a cleaning process such as laundry or hard surface cleaning such as dishwashing, and methods of producing the variants.

Claims (66)

1 . A subtilase variant comprising the substitutions X9R+X19L+X62D, wherein

(a) position numbers correspond to positions of the polypeptide of SEQ ID NO: 2;

(b) the variant has protease activity; and

(c) the variant has at least 80% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1;

and with the proviso that the variant does not comprise a histidine residue in position 14.

2 . The subtilase variant of claim 1 , comprising the substitutions S9R+R19L+N62D, and further comprising at least one alteration selected from the group consisting of S3T, S3A, N43R, V68A, N76D, P131*, A194P, V205I, Q245R, S259D, N261D and R275Q, wherein position numbers correspond to positions of the polypeptide of SEQ ID NO: 2.

3 . The subtilase variant of claim 2 , wherein the variant comprises a set of alterations selected from the group consisting of:

S3T+S9R+R19L+N62D+A194P;

S3T+S9R+R19L+N62D+A194P+Q245R+S259D;

S3T+S9R+R19L+N43R+N62D+A194P+R275Q;

S3T+S9R+R19L+N62D+P131*+A194P;

S3T+S9R+R19L+N62D+P131*+A194P+Q245R+S259D;

S3T+S9R+R19L+N43R+N62D+P131*+A194P+R275Q;

S3T+S9R+R19L+N43R+N62D+N76D+A194P;

S3T+S9R+R19L+N43R+N62D+N76D+P131*+A194P,

S3T+S9R+R19L+N62D+Q245R+S259D;

S3T+S9R+R19L+N43R+N62D+R275Q;

S3T+S9R+R19L+N62D+P131 *;

S3T+S9R+R19L+N62D+P131*+Q245R+S259D;

S3T+S9R+R19L+N43R+N62D+P131*+R275Q;

S3T+S9R+R19L+N43R+N62D+N76D;

S3T+S9R+R19L+N43R+N62D+N76D+Q245R+S259D;

S3T+S9R+R19L+N43R+N62D+N76D+P131 *;

S9R+A15T+G61E+N62D+V68A+A194P+V205I+Q245R+N261D;

S9R+A15T+G61E+V68A+A194P+V205I+Q245R+S259D+N261D;

S9R+R19L+N43R+N62D+R275Q;

S9R+R19L+N62D+P131 *;

S3A+S9R+R19L+N62D+Q245R+S259D;

S3A+S9R+R19L+N62D+A194P;

S9R+R19L+N43R+N62D+Q245R+S259D+R275Q;

S9R+R19L+N62D+P131*+Q245R+S259D;

S9R+R19L+N43R+N62D+A194P+R275Q;

S9R+R19L+N62D+P131*+A194P;

S9R+R19L+N43R+N62D+N76D;

S3A+S9R+R19L+N43R+N62D+Q245R+S259D+R275Q;

S3A+S9R+R19L+N62D+P131*+Q245R+S259D;

S3A+S9R+R19L+N62D+A194P+Q245R+S259D;

S3A+S9R+R19L+N43R+N62D+P131*+R275Q;

S3A+S9R+R19L+N43R+N62D+A194P+R275Q;

S3A+S9R+R19L+N62D+P131*+A194P;

S3A+S9R+R19L+N43R+N62D+N76D;

S9R+R19L+N43R+N62D+P131*+Q245R+S259D+R275Q;

S9R+R19L+N43R+N62D+A194P+Q245R+S259D+R275Q; and

S9R+R19L+N62D+P131*+A194P+Q245R+S259D.

4 . The subtilase variant of claim 3 , wherein the variant comprises SEQ ID NO: 1 with one of said sets of alterations.

5 . The subtilase variant of claim 1 , wherein the variant comprises the substitutions X3T+X9R+X19L+X62D+X194P.

6 . The subtilase variant of claim 5 , wherein the variant comprises SEQ ID NO: 1 with the substitutions S3T+S9R+R19L+N62D+A194P.

7 . The subtilase variant of claim 5 , further comprising at least one alteration selected from the group consisting of N43R, N76D, P131*, Q245R, S259D and R275Q, wherein position numbers correspond to positions of the polypeptide of SEQ ID NO: 2.

8 . The subtilase variant of claim 7 , comprising the substitutions Q245R+S259D.

9 . The subtilase variant of claim 8 , wherein the variant comprises SEQ ID NO: 1 with the substitutions S3T+S9R+R19L+N62D+A194P+Q245R+S259D.

10 . The subtilase variant of claim 1 , comprising the substitutions S3T+S9R+R19L+N62D+A194P.

11 . The subtilase variant of claim 1 , wherein the variant has at least 85%, but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1.

12 . The subtilase variant of claim 11 , wherein the variant has at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96% or at least 97% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1.

13 . The subtilase variant of claim 1 , wherein the variant has an improved stability in varied pH conditions compared to a reference protease having SEQ ID NO: 1 with the substitutions S9R+P14H+R19L+N62D.

14 . The subtilase variant of claim 1 , wherein the variant has an improved wash performance on a textile stain compared to the polypeptide of SEQ ID NO: 1.

15 . The subtilase variant of claim 14 , wherein the textile stain comprises blood, milk and ink.

16 . A granule comprising:

(a) a core comprising the subtilase variant of claim 1 , and optionally

(b) a coating consisting of one or more layer(s) surrounding the core.

17 . A detergent composition comprising a subtilase variant of claim 1 , and at least one detergent component.

18 . A method of cleaning laundry or a hard surface, the method comprising contacting an object with a subtilase variant of claim 1 under conditions suitable for cleaning the object.

19 . The method of claim 18 , wherein the cleaning is dishwashing.

20 . A method for obtaining a subtilase variant, the method comprising:

(a) providing a host cell comprising a polynucleotide encoding a variant of a parent protease comprising the mutations X9R+X19L+X62D compared to SEQ ID NO: 1, wherein position numbers correspond to positions of the polypeptide of SEQ ID NO: 2, wherein the variant has protease activity and a sequence identity to SEQ ID NO: 1 of at least 80% but less than 100%, and with the proviso that the variant does not comprise a histidine residue in position 14;

(b) cultivating the host cell under conditions suitable for expression of the variant; and

(c) recovering the variant.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2021
From: LENHARD, ROLF THOMAS; FRIIS, ESBEN PETER; BAUER, CARL MIKAEL; GAO, NAN
To: NOVOZYMES A/S
Reel/Frame 057009/0492 →
Priority Claims (1)
WO PCT/CN2019/073398 · Jan 28, 2019 · international
Continuity (1)
Related Publication 20220112476A1 · Apr 14, 2022
References Cited (15)
US 4661452A · Markussen · 1987 [cited by examiner]
US 20040147008A1 · Draborg · 2004 [cited by applicant]
US 20070161531A1 · Draborg · 2007 [cited by examiner]
US 20180148670A1 · O'connell · 2018 [cited by applicant]
CN 106661566A · 2017 [cited by applicant]
CN 107075493A · 2017 [cited by applicant]
JP 2009500023A · 2009 [cited by applicant]
WO WO2004041979A2 · 2004 [cited by examiner]
WO 2007006305A1 · 2007 [cited by applicant]
WO 2016001449A1 · 2016 [cited by applicant]
WO 2016087617A1 · 2016 [cited by applicant]
WO 2018118950A1 · 2018 [cited by applicant]
Timothy et al., 2004, Household & Personal Products Industry 41, 20-23. [cited by applicant]
OSTEN, 1993, Studies in organic chemistry, 133-144. [cited by applicant]
Novozymes A/S, 2013, IP.com No. IPCOM000231510D. [cited by applicant]